✦ LIBER ✦

Treatment of chronic hepatitis C with PEGylated interferon and ribavirin

✍ Scribed by Markus Cornberg; Heiner Wedemeyer; Michael P. Manns

Publisher: Springer
Year: 2002
Tongue: English
Weight: 513 KB
Volume: 4
Category: Article
ISSN: 1522-8037
DOI: 10.1007/s11894-002-0034-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vitiligo associated with pegylated inter

Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: A case report

✍ Krzysztof Tomasiewicz; Romana Modrzewska; Grażyna Semczuk 📂 Article 📅 2006 🏛 Springer Healthcare Communications 🌐 English ⚖ 201 KB

Incidence of Neutropenia and Infections

Incidence of Neutropenia and Infections During Combination Treatment of Chronic Hepatitis C with Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin

✍ M. G. Antonini; S. Babudieri; I. Maida; C. Baiguera; B. Zanini; L. Fenu; G. Dett 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 271 KB

Chronic hepatitis C: Treatment of pegyla

Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders

✍ Mitchell L. Shiffman 📂 Article 📅 2006 🏛 Current Science Inc. 🌐 English ⚖ 178 KB

Chronic hepatitis C: Treatment of pegyla

Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders

✍ Mitchell L. Shiffman 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 177 KB

Pegylated interferon plus ribavirin in c

Pegylated interferon plus ribavirin in chronic hepatitis c

✍ Bruce R. Bacon 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 38 KB

Merimepodib, pegylated interferon, and r

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders

✍ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a